Alogliptin (SYR-322)是一种强效、选择性口服DPP-4抑制剂，对DPP-8和DPP-9的选择性高出10,000倍以上，可用于2型糖尿病相关研究。
| 英文别名 (English Synonym) | Alogliptin (SYR-322) |
| 中文名称 (Chinese Name) | 阿格列汀 |
| 靶点 (Target) | DPP-4 |
| 通路 (Pathway) | Protease/Metabolic Enzyme |
| CAS号 (CAS NO.) | 850649-61-5 |
| 分子式 (Formula) | C18H21N5O2 |
| 分子量 (Molecular Weight) | 339.39 |
| 纯度 (Purity) | ≥98% |
| 溶解性 (Solubility) | 溶于DMSO |
-25~-15℃保存，有效期3年
[1] Ta NN, Li Y, Schuyler CA, Lopes-Virella MF, Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis. 2010 Dec;213(2):429-35. doi: 10.1016/j.atherosclerosis.2010.08.064. Epub 2010 Aug 26. PMID: 20843518.
[2] Feng J, Zhang Z, Wallace MB, Stafford JA, Kaldor SW, Kassel DB, Navre M, Shi L, Skene RJ, Asakawa T, Takeuchi K, Xu R, Webb DR, Gwaltney SL 2nd. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007 May 17;50(10):2297-300. doi: 10.1021/jm070104l. Epub 2007 Apr 19. Erratum in: J Med Chem. 2008 Jul 24;51(14):4357. PMID: 17441705.
